TY - JOUR T1 - Comparison of the Personality Dimensions of Patients with Major Depressive Disorder using Serotonin Reuptake Inhibitors Antidepressant Drugs, with Serotonin Reuptake Inhibitors and Triangular Drugs Combination TT - مقایسه ابعاد شخصیتی بیماران مبتلا به افسردگی اساسی مصرف کننده داروهای ضدافسردگی بازدارنده جذب مجدد سروتونین با داروهای بازدارنده جذب مجدد سروتونین و داروهای سه‌حلقه‌ای JF - jhpm.ir JO - jhpm.ir VL - 7 IS - 1 UR - http://jhpm.ir/article-1-887-en.html Y1 - 2018 SP - 9 EP - 16 KW - Personality KW - Temperament KW - Character KW - Antidepressant drugs. N2 - Introduction: Neurotransmitter systems, involved in depressive disorders, are in line with personality dimensions. The present study aimed at comparing personality dimensions of individuals with major depressive disorders using Selective Serotonin Reuptake Inhibitors (SSRIs) drugs with those of individuals using Tricyclic Antidepressant (TCA) in combination with SSRIs. Methods: The present study was descriptive-comparative, which was carried out during year 2017 in two groups of 37 patients with major depressive disorder, who used Selective Serotonin Reuptake Inhibitors (SSRIs) with those of individuals using Tricyclic Antidepressant (TCA) in combination with SSRIs. Samples were selected by the convince sampling method from Baqiyatallah al-Azam hospital, Taleghani, Faculty of Psychology of Tehran University and Sepehr clinics. For data collection, the “Temperament and Character Inventory” (TCI-56) was used. The validity and reliability of this inventory has been confirmed in previous studies. Data were analyzed with the SPSS version 24 software. Results: The two groups did not differ significantly in terms of personality traits. In other words, the mean personality characteristics did not differ significantly between the two groups (P < 0.01). Conclusions: According to the results of this study, prescribing both drug groups is recommended to increase the desirable personality scores and to reduce undesirable scores in the treatment of patients with depressive disorder. M3 10.21859/jhpm-08012 ER -